Market Place
Sourcing Support
Allarity Granted European Patent For DRP® Diagnostic
22 Oct 2024 //
GLOBENEWSWIRE
Allarity Regains NASDAQ Minimum Bid Price Compliance
10 Oct 2024 //
GLOBENEWSWIRE
Allarity Adds Leaders To Advance Stenoparib PARP Program
03 Oct 2024 //
GLOBENEWSWIRE
Allarity Reports Stenoparib Treatment In Ovarian Cancer
16 Sep 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Announces New CFO And Inducement Grants
13 Sep 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Takes Step To Regain Nasdaq Compliance
11 Sep 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
26 Jul 2024 //
GLOBENEWSWIRE
Allarity Urges Shareholders To Support Reverse Split And Share Decrease
24 Jul 2024 //
GLOBENEWSWIRE
Allarity warned of pending SEC enforcement action over FDA meeting conduct
22 Jul 2024 //
FIERCE BIOTECH
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
22 Jul 2024 //
GLOBENEWSWIRE
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining
27 Jun 2024 //
GLOBENEWSWIRE
Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer
25 Jun 2024 //
GLOBENEWSWIRE
Allarity Regains Nasdaq Minimum Stockholders` Equity Compliance
20 May 2024 //
GLOBENEWSWIRE
Allarity Reports Q1 Results, Clinical Benefits, NASDAQ Compliance
14 May 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Converts Series A Preferred And Warrants To Common Stock
07 May 2024 //
GLOBENEWSWIRE
Allarity Exceeds Nasdaq Minimum Equity, Withdraws S-1 Filing
06 May 2024 //
GLOBENEWSWIRE
Allarity Stenoparib Shows Clear Clinical Benefit and Achieves Milestone
02 May 2024 //
GLOBENEWSWIRE
Allarity Regains NASDAQ Minimum Bid Compliance
29 Apr 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Receives Nasdaq Listing Rule Extension
17 Apr 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
04 Apr 2024 //
GLOBENEWSWIRE
Allarity Strategic Focus on Accelerating Stenoparib Toward Regulatory Approval
27 Mar 2024 //
GLOBENEWSWIRE
Allarity Receives Extension from Nasdaq Hearings Panel to Regain Compliance
25 Mar 2024 //
GLOBENEWSWIRE
Allarity Therapeutics Reports Full Year 2023 Financial Results
08 Mar 2024 //
GLOBENEWSWIRE
Allarity Therapeutics to Present at Biomarkers 2024
28 Feb 2024 //
GLOBENEWSWIRE
Novartis ends license agreement for cancer drug with Allarity Therapeutics
02 Feb 2024 //
ENDPTS
Allarity loses rights to Novartis cancer drug over payments
02 Feb 2024 //
FIERCE BIOTECH
Allarity Therapeutics Announces Thomas Jensen as Interim CEO
12 Dec 2023 //
GLOBENEWSWIRE
Allarity`s Phase 2 Stenoparib Data Indicates Clinical Benefit in Ovarian Cancer
05 Dec 2023 //
GLOBENEWSWIRE
Allarity Therapeutics to Present at Biomarkers Europe 2023
02 Oct 2023 //
GLOBENEWSWIRE
PLOS ONE Publishes Data on Allarity DRP® Companion Diagnostic for Dovitinib
30 Aug 2023 //
GLOBENEWSWIRE
Allarity Therapeutics and FivepHusion Announce Collaboration
31 Jul 2023 //
GLOBENEWSWIRE
Allarity Therapeutics Appoints Three Accomplished Biotechnology Executives
24 Jul 2023 //
GLOBENEWSWIRE
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
06 Jul 2023 //
GLOBENEWSWIRE
Data from Allarity`s PII Trial of IXEMPRA Indicate Potential for Benefit in DRP
05 Jul 2023 //
GLOBENEWSWIRE
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
28 Jun 2023 //
GLOBENEWSWIRE
Allarity Announces Clarification of Effective Date for Reverse Stock Split
27 Jun 2023 //
GLOBENEWSWIRE
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
20 Jun 2023 //
GLOBENEWSWIRE
First Prospective Clinical Validation of Allarity`s DRP® Companion Diagnostic
30 May 2023 //
GLOBENEWSWIRE
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
19 Apr 2023 //
GLOBENEWSWIRE
Abstract Evaluating Allarity`s DRP Companion Diagnostic for Cisplatin Accepted
11 Apr 2023 //
GLOBENEWSWIRE
Allarity Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Studies
28 Mar 2023 //
GLOBENEWSWIRE
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
24 Mar 2023 //
GLOBENEWSWIRE
Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib
20 Mar 2023 //
GLOBENEWSWIRE
Allarity Announces Adjournment of 2023 Annual Meeting of Stockholders
20 Jan 2023 //
GLOBENEWSWIRE
Allarity Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
01 Dec 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Announces Adjournment 2022 Annual Meeting of Stockholders
07 Nov 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Reports Second Quarter 2022 Financial Results
11 Oct 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin
26 Sep 2022 //
GLOBENEWSWIRE
Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
16 Sep 2022 //
GLOBENEWSWIRE
Allarity Receives Nasdaq Listing Rule 5250(c)(1)
26 Aug 2022 //
GLOBENEWSWIRE
FDA sinks Allarity’s plans for lead oncology asset
03 Aug 2022 //
FIERCEBIOTECH
Allarity Tx Refocuses Oncology Pipeline Strategy Towards Combination Therapies
02 Aug 2022 //
GLOBENEWSWIRE
Allarity Tx Bolsters Its Board of Directors; Appoints David A. Roth, M.D.
11 Jul 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Announces Executive Leadership Transition
29 Jun 2022 //
GLOBENEWSWIRE
Allarity Tx Strengthens Scientific Advisory Board; Appoints Roberto Pili, M.D.
15 Jun 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Reports First Quarter 2022 Financial Results
27 May 2022 //
GLOBENEWSWIRE
Financial Results For the Fourth Quarter and Full Year 2021 Financial Results
18 May 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Reports Fourth Quarter, Full Year 2021 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance
22 Apr 2022 //
GLOBENEWSWIRE
Allarity Tx Provides Update on Dovitinib Program
15 Mar 2022 //
GLOBENEWSWIRE
